Key facts
- It has raised $201.3M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Bpifrance, La French Tech, Sofinnova Partners, Cathay Capital, BNP Paribas Développement — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for TISSIUM
- ·The full record, as it builds
Funding rounds
No funding rounds for TISSIUM are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TISSIUM
Developer of biodegradable programmable polymer technology designed for tissue reconstruction and adaptable for use in multiple clinical areas. The company's technology uses biomorphic reconstructive polymers for biodegradable sealants and adhesives for surgical-wound closure that are non-toxic, designed to bind strongly to tissues and deliver immediate wound closure within the dynamic environments of the body, enabling surgeons to treat patients with a polymer that can be used in the fields of tissue repair and localized drug delivery.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2013
- Employees
- 128
- Website
- tissium.com/
- Ownership
- Privately Held (backing)
TISSIUM doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TISSIUM shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TISSIUM in its N-PORT filings yet. We sweep new filings monthly.